30-Nov-2010 - Sun Pharmaceutical Industries Limited

Sun Pharma Announces USFDA Tentative Approval for Generic Cymbalta

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.

These generic duloxetine hydrochloride delayed-release capsules, 20 mg (base), 30 mg (base), and 60 mg (base) are indicated in the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) and Diabetic Peripheral Neuropathic Pain (DPNP).

Facts, background information, dossiers
More about Sun Pharmaceutical Industries
More about FDA